These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36428095)

  • 1. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of different health warning label and reduced exposure messages in IQOS ads on perceptions among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Abroms LC; Khayat A; Romm KF; Levine H; Bar-Zeev Y
    Prev Med Rep; 2023 Jun; 33():102209. PubMed ID: 37223575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
    Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
    Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to IQOS ads and reduced exposure claims, and association with perceived risk from COVID-19 on IQOS purchase and use intentions: results from a web-based survey.
    Sharma A; Fix B; Hyland A; Bansal-Travers M; Quisenberry A; O'Connor R
    Front Public Health; 2023; 11():1307484. PubMed ID: 38269390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
    Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
    Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
    Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
    Tob Control; 2023 Mar; ():. PubMed ID: 36958825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
    Lempert LK; Bialous S; Glantz S
    Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.
    Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceived relative harm of heated tobacco products (IQOS), e-cigarettes, and cigarettes among adults in Canada: Findings from the ITC Project.
    Sutanto E; Miller CR; Smith DM; O'Connor RJ; Gravely S; Hammond D; Hyland A; Cummings KM; Quah ACK; Fong GT; Agar TK; Goniewicz ML
    Tob Induc Dis; 2020; 18():81. PubMed ID: 33013277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Organic," "Natural," and "Additive-Free" Cigarettes: Comparing the Effects of Advertising Claims and Disclaimers on Perceptions of Harm.
    Baig SA; Byron MJ; Lazard AJ; Brewer NT
    Nicotine Tob Res; 2019 Jun; 21(7):933-939. PubMed ID: 29529277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
    McKelvey K; Baiocchi M; Halpern-Felsher B
    Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of advertising features on smokers' and non-smokers' perceptions of a reduced nicotine cigarette modified risk tobacco product.
    Mercincavage M; Pacek LR; Thrasher J; Cappella JN; Delnevo C; Donny EC; Strasser AA
    Tob Control; 2023 Jan; 32(1):6-12. PubMed ID: 33858965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smokers' Exposure to Perceived Modified Risk Claims for E-Cigarettes, Snus, and Smokeless Tobacco in the United States.
    Wackowski OA; O'Connor RJ; Pearson JL
    Nicotine Tob Res; 2021 Feb; 23(3):605-608. PubMed ID: 32812028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims.
    Popova L; Lempert LK; Glantz SA
    Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IQOS Use and Interest by Sociodemographic and Tobacco Behavior Characteristics among Adults in the US and Israel.
    Levine H; Duan Z; Bar-Zeev Y; Abroms LC; Khayat A; Tosakoon S; Romm KF; Wang Y; Berg CJ
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.